Related Experiment Video
Updated: Jan 11, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
20 years of taxane therapy in prostate cancer - the past, present and future
Marc Carceles-Cordon1, Veronica Rodriguez-Bravo1,2, Daniel P Petrylak3
1Urology Department, Mayo Clinic, Rochester, MN, USA.
Abstract:
2024 marked the twentieth anniversary of FDA approval for taxane therapy, namely docetaxel, in the treatment of advanced prostate cancer. Approval of this treatment modality signified a breakthrough in the field, as it demonstrated for the first time that a non-antiandrogen targeting agent could significantly improve survival of patients with prostate cancer. New evidence has further solidified the role of taxanes, demonstrating that it improves survival when used in combination with androgen-targeting therapy in early-stage metastatic hormone-sensitive prostate cancer. Consequently, taxane therapy is currently considered a gold standard and mainstay in the treatment of prostate cancer. In this Review, we present an up-to-date analysis of the pivotal role of taxanes in the treatment of prostate cancer, discuss reasons why taxanes are effective and discuss how the mechanisms that confer resistance to taxanes in prostate cancer might be exploited to develop more effective therapeutic strategies.
Insights
Taxane therapy, including docetaxel, has been a breakthrough in advanced prostate cancer treatment for 20 years. New evidence confirms taxanes improve survival in combination therapies for early-stage prostate cancer.
Area of Science:
- Oncology
- Pharmacology
Background:
- Taxane therapy, specifically docetaxel, received FDA approval for advanced prostate cancer treatment in 2004.
- This marked a significant advancement, showing a non-antiandrogen agent could improve patient survival.
- Recent findings reinforce taxanes' efficacy, particularly when combined with androgen-targeting therapy in early-stage metastatic hormone-sensitive prostate cancer.
Purpose of the Study:
- To provide an updated analysis of taxanes' role in prostate cancer treatment.
- To explore the mechanisms underlying taxane effectiveness.
- To discuss strategies for overcoming taxane resistance in prostate cancer therapy.
Main Methods:
- Review of pivotal studies and clinical trials on taxane therapy in prostate cancer.
- Analysis of pharmacological data and mechanisms of action for taxanes.
- Examination of resistance mechanisms and potential therapeutic targets.
Main Results:
- Taxane therapy, including docetaxel, is a gold standard and mainstay in prostate cancer treatment.
- Combination therapy with taxanes and androgen-targeting agents improves survival in early-stage metastatic hormone-sensitive prostate cancer.
- Understanding taxane resistance mechanisms is crucial for developing novel therapeutic strategies.
Conclusions:
- Taxanes play a pivotal role in improving survival outcomes for prostate cancer patients.
- Further research into taxane resistance mechanisms can lead to more effective treatment strategies.
- Taxane-based therapies remain a cornerstone in the management of prostate cancer.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:15Drugs that Stabilize Microtubules
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:21Cancer Survival Analysis